Dulaedge 100mg Injection

Dulaedge 100mg Injection

Dulaedge 100mg Injection is a high-potency hematological intervention containing Iron Sucrose (20 mg/mL), a complex of polynuclear iron(III)-hydroxide in sucrose, specifically engineered for the clinical management of iron deficiency anemia (IDA). Utilizing a unique “Carbohydrate-Stabilized” matrix, this injection works by replenishing the body’s iron stores and increasing hemoglobin levels. Unlike oral iron supplements that are often limited by gastrointestinal absorption barriers, Iron Sucrose is delivered directly into the systemic circulation. This targeted biochemical action provides a decisive therapeutic response by making iron immediately available for erythropoiesis (the production of red blood cells) within the bone marrow.

Key Features

• Specifically bypasses the digestive tract to provide an immediate source of iron for red blood cell synthesis.
• Clinically recognized for its stable sucrose complex, which reduces the risk of anaphylactoid reactions compared to older iron dextran formulations.
• Essential for patients undergoing Erythropoietin (EPO) therapy to ensure adequate iron substrate for blood production.
• Its unique molecular structure ensures efficient uptake by the reticuloendothelial system for storage and future use.
• Specifically engineered to be administered via intravenous infusion, reducing the gastric distress common with oral iron salts.

Key Ingredients

• Iron Sucrose (20 mg elemental iron per mL)
• Sodium Hydroxide
• Water for Injection

Precautions

• Must be administered only by a qualified healthcare professional in a clinical setting equipped for emergency resuscitation.
• Patients should be monitored closely for at least 30 minutes following each injection for signs of allergic reactions or hypotension.
• Periodic monitoring of serum ferritin and transferrin saturation is required to prevent the development of hemosiderosis.
• Use during the first trimester of pregnancy should be strictly evaluated by a physician; consult a doctor if breastfeeding.
• Some patients may experience a temporary metallic taste, nausea, or dizziness during or immediately after the infusion.
• Dulaedge should not be mixed with other medications or added to parenteral nutrition solutions.

How to Use

• The solution must be inspected visually for particulate matter and discoloration prior to administration.
• Administered strictly via the intravenous route, either by slow semi-undiluted injection or by intravenous drip infusion.
• When infused, it must be diluted exclusively with 0.9% w/v Sodium Chloride solution to maintain complex stability.
• The total dosage is individually calculated by a physician based on the patient’s hemoglobin deficit and body weight (using the Ganzoni formula).
• Typically administered two to three times per week, depending on the clinical urgency and the patient’s hematological response.
• Ensure the patient remains seated or reclined for a short period following the infusion to prevent orthostatic hypotension.

Legal Disclaimer: Dulaedge 100mg Injection is a prescription-only hematological product. Individual results vary based on the underlying cause of anemia and the patient’s overall health status. This product is not intended for the treatment of anemias not caused by iron deficiency. This information is for educational purposes and is not a substitute for professional medical consultation or hospital protocols.